Dannielle Appelhans, MBA

Dannielle Appelhans is the President and Chief Executive Officer (CEO) of COUR, bringing extensive operational and leadership experience in the biotechnology industry and dedication to providing innovative therapies. She joined COUR in 2023 as Chief Operating Officer (COO) and became CEO in 2024. Prior to joining COUR, Dannielle served as the CEO of Rubius Therapeutics, Inc., a publicly traded and clinical-phase biopharmaceutical company that pioneers cellular medicines. She previously served as its COO. Since 2022, Dannielle has served on the Board of Directors and as a member of the Nominating and Governance Committee for Generation Bio Co. Prior to Rubius, Dannielle held roles of increasing responsibility at Novartis in operations and strategy, including Senior Vice President, Head of Global Supply Chain, Senior Vice President of Technical Operations and Chief Technical Officer at Novartis Gene Therapies. Before Novartis, she was a Senior Engagement Manager at McKinsey & Company. Previously, she held roles of increasing responsibility at Eli Lilly and Company. Dannielle earned a Master of Science in mechanical engineering from Massachusetts Institute of Technology’s School of Engineering, an MBA from Massachusetts Institute of Technology’s Sloan School of Management, and a Bachelor of Science in mechanical engineering from the University of Michigan.